FINWIRES · TerminalLIVE
FINWIRES

Prinx Chengshan Unit to Acquire Equipment for Malaysian Tire Production Project

By

Prinx Chengshan Holdings (HKG:1809) unit Prinx Tire (Malaysia) agreed to acquire certain equipment from Qingdao MESNAC Machinery and Electric Engineering for 116.1 million yuan, according to a May 29 Hong Kong bourse filing.

Shares of the tire manufacturer were up nearly 3% in Monday afternoon trading.

The equipment comprises 55-inch and 48-inch hydraulic curing presses for all-steel tires, as well as an open mixing mill.

The purchases will facilitate the firm's construction of a tire production base in Malaysia.

Related Articles

Asia

FDB Holdings Eyes HK$79.1 Million from Rights Issue

FDB Holdings (HKG:1826) is proposing a one-for-two rights share issue to raise up to around HK$79.1 million in net proceeds, according to a May 29 Hong Kong bourse filing.Shares of the contracting services firm were up nearly 4% in Monday afternoon trading.The firm is looking to issue 799.2 million shares at HK$0.10 apiece to qualifying shareholders under the issue.The company will use proceeds to fulfill the upfront payments and costs related to certain overseas expansion, EPC projects, and setting up overseas offices; as well as for general working capital.

$HKG:1826
Asia

Basecare Medical Gets Registration Certificate for Gem Egg Retrieval Solution in China

Suzhou Basecare Medical (HKG:2170) obtained the class III medical device registration certificate for the egg retrieval solution in its Gems series from China's National Medical Products Administration, according to a May 29 Hong Kong bourse filing.Shares of the genetic technology research firm were down over 2% in Monday afternoon trading.The egg retrieval solution is a core reagent in IVF procedures and provides essential preconditions for subsequent fertilization, cleavage, and blastocyst development.

$HKG:2170
Asia

Zhejiang Huahai Pharmaceutical Secures Two Drug Approvals in China

Zhejiang Huahai Pharmaceutical (SHA:600521) obtained registration for two drugs from China's medical products administrator.Brexpiprazole tablets are indicated for adult schizophrenia and isavuconazonium sulfate injection for invasive aspergillosis and mucormycosis, according to a weekend filing with the Shanghai bourse.Shares of the drugmaker closed 1% higher Monday.

$SHA:600521